News | June 22, 2022
MedC Biopharma partners with A2W Pharma to develop cannabinoid therapeutics
Bringing next-gen cannabinoid therapeutics to cancer patients
Bringing next-gen cannabinoid therapeutics to cancer patients
The company is now introducing the product into the India pharmaceutical market.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Wedgewood Pharmacy operates compounding pharmacies that offers sterile and non-sterile compounded medications for animal patients in 50 states.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated
